. home.aspx



Biothera Pharmaceuticals Presents Data Broadening Imprime PGG Mechanism of Action

November 13, 2017 / GLOBE NEWSWIRE

Biothera Pharmaceuticals, Inc. announced today the presentation of clinical and preclinical research supporting the mechanism of action for the Company’s cancer immunotherapy Imprime PGG, which is currently being evaluated in combination with immune checkpoint inhibitor therapy in multiple Phase 2 clinical trials.